1	Circulating microRNAs are related to cognitive domains in the general
2	population
3	
4	Authors
5	Konstantinos Melas ^a , Valentina Talevi ^a , Rika Etteldorf ^a , Santiago Estrada ^{a,b} , Dennis M.
6	Krüger ^c , Tonatiuh Pena ^{c, d} , N. Ahmad Aziz ^{a,e} , André Fischer ^{c,f,g} , Monique M.B. Breteler ^{a,h}
7	Affiliations
8	^a Population Health Sciences, German Centre for Neurodegenerative Diseases (DZNE),
9	Venusberg-Campus 1/99, 53127 Bonn, Germany
10	^b AI in Medical Imaging, German Centre for Neurodegenerative Diseases (DZNE),
11	Venusberg-Campus 1/99, 53127 Bonn, Germany
12	^c Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German
13	Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075 Göttingen,
14	Germany
15	^d Bioinformatics Unit, German Centre for Neurodegenerative Diseases (DZNE), Von-
16	Siebold-Str. 3a, 37075 Göttingen, Germany
17	^e Department of Neurology, Faculty of Medicine, University of Bonn, Venusberg-Campus
18	1/80, 53127 Bonn, Germany
19	^f Department for Psychiatry and Psychotherapy, University Medical Center Göttingen, Von-
20	Siebold-Str. 5, 37075 Göttingen, Germany
21	^g Cluster of Excellence MBExC, University of Göttingen & University Medical Center
22	Goettingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany

25 institute for fifedical Bronned J, informatios and Epidemiorogy (iniBiE), i acate	ilty of	, Facult	(IMBIE)	logy	emic	oide	Εŗ	and	Informatics	etry,	Biomet	Iedical	for l	Institute	23 ^h
--	---------	----------	---------	------	------	------	----	-----	-------------	-------	--------	---------	-------	-----------	-----------------

24 Medicine, University of Bonn, Venusberg-Campus 1/11, 53127 Bonn, Germany

25 Corresponding Author

- 26 Monique M.B. Breteler, MD PhD
- 27 Director of Population Health Sciences
- 28 German Center for Neurodegenerative Diseases (DZNE)
- 29 Venusberg-Campus 1, Building 99
- 30 53127 Bonn
- 31 Germany
- 32 Tel +49 228 43302-929
- 33 Email: monique.breteler@dzne.de
- 34 ORCID: 0000-0002-0626-9305
- 35
- 36 Total word count (title page, abstract, text, references, tables, and figure legends): 10792
- 37 Word count for abstract: 150
- 38 Number of tables: 1
- 39 Number of figures: 6
- 40
- 41 **Declarations of interest**: none
- 42

43	Contact data of authors
44	Konstantinos Melas
45	E-mail: Konstantinos.melas@dzne.de
46	ORCID: 0009-0000-5206-5322
47	
48	Valentina Talevi
49	E-Mail: Valentina.Talevi@dzne.de
50	ORCID: 0000-0003-4418-7439
51	
52	Rika Etteldorf
53	E-mail: Rika.Etteldorf@dzne.de
54	ORCID: 0009-0008-6317-7934
55	
56	Santiago Estrada
57	E-Mail: Santiago.Estrada@dzne.de
58	ORCID: 0000-0003-0339-8870
59	
60	Dennis M. Krüger
61	E-mail: Dennis.Krueger@dzne.de
62	ORCID: 0000-0003-1950-9547

63

- 64 Tonatiuh Pena
- 65 E-Mail: Tonatiuh.Pena@dzne.de
- 66 ORCID: 0000-0002-9329-8912

67

- 68 N. Ahmad Aziz
- 69 E-Mail: Ahmad.Aziz@dzne.de
- 70 ORCID: 0000-0001-6184-458X
- 71
- 72 Andre Fischer
- 73 Email: Andre.Fischer@dzne.de
- 74 ORCID: 0000-0001-8546-1161

76 ABSTRACT

INTRODUCTION: Circulating microRNAs have been suggested as candidates for detecting 77 78 and preventing subclinical cognitive dysfunction. However, replication of previous findings and identification of novel microRNAs associated with cognitive domains, including their 79 relation to brain structure and the pathways they regulate, are still lacking. 80 81 METHODS: We examined circulating microRNAs and microRNA co-expression clusters in 82 relation to cognitive domains, structural MRI measures, and target gene expression in 2869 83 participants of a population-based cohort. 84 **RESULTS**: Five previously identified and 10 novel microRNAs were associated with cognitive domains. Importantly, seven of these microRNAs were also associated with cortical 85 86 thickness and two with hippocampal volume. Functional genomics analysis showed that the 87 identified microRNAs regulated genes in pathways like neurogenesis, axon guidance, and 88 synapse assembly. **DISCUSSION:** We identified microRNAs associated with cognitive domains, brain regions, 89 90 and neuronal processes affected by aging and neurodegeneration, making them promising 91 candidate blood-based biomarkers or therapeutic targets of subclinical cognitive dysfunction. 92 93 **KEYWORDS** 94 microRNA; cognition; population-based; biomarker; cortical thickness; miR-215-5p; miR-192-5p; miR-134-5p; miR-92b-3p; miR-10401-3p; miR-4677-5p; miR-4732-3p; miR-92a-3p; 95

96 miR-128-3p; miR-125b-5p

98 **1 BACKGROUND**

99 Mitigating the impact of cognitive aging remains one of the biggest challenges of the 21st 100 century [1]. Early detection of subclinical cognitive dysfunction is necessary to enable 101 interventions at the earliest stages of its pathophysiology [2]. Currently, tailored 102 neuropsychological test batteries are the gold standard for detecting cognitive dysfunction. 103 However, such batteries can be time-consuming, require experienced examiners, and are 104 dependent on individual traits such as language and cultural background. Moreover, their 105 sensitivity in the very early stages of cognitive dysfunction, and in highly educated persons, 106 is limited [3]. The identification of blood-based molecular biomarkers of subclinical 107 cognitive dysfunction could facilitate earlier and more reliable detection of individuals at risk 108 of accelerated cognitive aging or neurodegeneration [4]. Additionally, such biomarkers might 109 point to specific pathophysiologic processes involved in cognitive aging, and thus help the 110 development of targeted interventions.

111 Various blood-based biomarkers have been investigated for the early detection of cognitive 112 dysfunction, including neurodegenerative [4], lipidomic, inflammatory [5] and proteomic [6] 113 markers. A highly promising line of research focuses on microRNAs [7,8]. These small, 114 endogenous, non-coding RNAs bind to target genes, mainly through base pairing, leading to 115 degradation of these genes or inhibition of their translation. A single microRNA can have 116 several physiological effects through the regulation of multiple genes [9]. Additionally, 117 microRNAs are highly expressed in the brain, where they regulate functions like synaptic 118 plasticity and memory. Brain-enriched microRNAs can cross the blood-brain barrier and 119 enter the peripheral circulation, where they remain stable for extended periods [8]. Thus, 120 microRNAs have been investigated for the diagnosis and treatment of neurodegenerative 121 diseases [10]. For example, circulating microRNA-based panels were shown to have high 122 accuracy in diagnosing Alzheimer's Disease (AD), and one such diagnostic panel has entered

phase I of clinical development [11]. Conversely, microRNA-based therapeutics have been
hindered by the incomplete characterization of the functions of tested microRNAs, which can
lead to unforeseen side effects [11].

126 To assess whether circulating microRNAs can be employed for early detection or prevention of cognitive dysfunction, their association with cognition must be investigated in non-127 128 demented individuals, and their functions must be better understood. In the past, a few 129 population-based studies identified microRNA signatures associated with general cognitive 130 function and decline [12,13], verbal memory changes longitudinally [14], or multiple 131 cognitive domains cross-sectionally [15]. A recent study identified a three-microRNA 132 signature related to cognitive function and decline, by combining population-level and animal model data [16]. However, most of these studies had relatively small samples, potentially 133 134 limiting their capability to detect microRNAs with weaker effect sizes. Specifically, the 135 largest study included 1615 participants [12], while the rest had sample sizes ranging from 136 132 [16] to 830 [15] participants. Moreover, the only study that examined more than one 137 cognitive domain evaluated only a small number (n=38) of microRNAs previously linked to 138 AD [15]. Thus, there is a need for studies combining larger sample sizes, multiple cognitive 139 domains, and the untargeted evaluation of many microRNA transcripts. In addition, it is 140 worth noting that only five microRNAs (miR-4732-3p, miR-363-3p, miR-181a-5p, miR-141 146a-5p and let-7c-5p) overlapped among at least two of these studies. This reflects a greater 142 problem in microRNA research. The large heterogeneity in microRNA sampling and 143 quantification methods often leads to inconsistent results among studies, which highlights the 144 need for replication [17]. Lastly, none of these studies examined the association of cognition-145 related microRNAs with brain structure or gene expression. This could provide information 146 on key microRNA-regulated biological pathways, enabling their use as therapeutic targets against cognitive decline. 147

Here, we aimed to first identify blood-circulating microRNAs associated with the major domains of cognitive function, by replicating the results of previous studies and identifying novel associations in a population-based cohort consisting of 2869 individuals. Next, we determined which of the identified cognition-related microRNAs were associated with brain structure. Lastly, leveraging gene expression data through a functional genomics approach, we elucidated the molecular pathways through which the identified microRNAs could affect cognitive function and brain structure.

2 METHODS 155

156 2.1 Study Design

165

166

157 Our analysis was based on cross-sectional baseline data from the Rhineland Study, an 158 ongoing prospective, population-based cohort study in Bonn, Germany. All residents of two 159 geographically defined areas in Bonn, aged 30 years or older, were invited to participate in 160 the study. The only exclusion criterion was an insufficient command of the German language 161 to provide informed consent. One of the main goals of the Rhineland Study is to investigate 162 biomarkers and determinants of aging and age-related diseases in the general population, 163 following a deep-phenotyping approach. Each participant undergoes a comprehensive 7-hour 164 examination protocol, which includes detailed questionnaires, brain imaging,

neuropsychological examinations, and blood sample analyses.

2.2 Standard protocol approvals, registrations, and participant consent

167 Approval to undertake the study was obtained from the ethics committee of the University of 168 Bonn, Medical Faculty. The study is carried out in accordance with the recommendations of 169 the International Conference on Harmonization Good Clinical Practice standards. We 170 obtained written informed consent from all participants in accordance with the Declaration of 171 Helsinki.

172 2.3 Study population

- 173 Biomaterial was selected from the first 3000 participants of the Rhineland Study who
- 174 provided blood samples for microRNA sequencing. MicroRNA expression data was missing
- 175 due to technical issues (n=33) or exclusion during quality control (n=38). From the remaining
- 176 2929, we excluded 60 participants because of missing cognition data (due to:

177 contraindications/exclusion criteria, n=7; participant refusal, n=3; technical issues, n=3; 178 exclusion during quality control, n=9; a combination of the above, n=38), leaving 2869 179 participants with both microRNA expression and cognitive performance data ("cognition 180 dataset"). Brain imaging data were available for a subset of 2045 participants of the cognition 181 dataset (brain imaging data missing due to: contraindications/exclusion criteria, n=452; 182 participant refusal, n=330; other/ unknown reasons, n=42). Gene expression and blood cell 183 count data were available for a subset of 2138 participants of the cognition dataset (gene expression data missing due to: technical issues, n=475; exclusion during quality control, 184 185 n=129; blood cell count data missing due to: technical issues, n=126; unknown reasons, n=1). 186 The overlap of the subset with complete MRI data and the subset with complete gene 187 expression and blood cell count data consisted of 1534 participants.

188 **2.4 Blood sample acquisition and RNA isolation**

189 Blood samples were collected between 7:00 to 9:45 in the morning from an antecubital or 190 dorsal hand vein. On some occasions, blood sample collection was performed on a different 191 visit than the cognitive evaluation. The time difference between the two visits was usually 192 less than one month. Whole blood samples for microRNA and gene expression (messenger 193 RNA) sequencing were collected in PAXgene Blood RNA tubes (PreAnalytix/Qiagen) and 194 stored at -80° Celsius. Before sequencing, PAXgene Blood RNA Tubes were thawed and 195 incubated at room temperature to increase RNA yield. Total RNA was isolated according to 196 manufacturer's instructions using the PAXgene Blood miRNA Kit and following the 197 automated purification protocol (PreAnalytix/Qiagen).

198 **2.5 MicroRNA and gene expression measurement**

199 We performed the microRNA sequencing on the Illumina HiSeq 2000 over 44 batches, and 200 the RNA sequencing on the NovaSeq6000 platform over 28 batches. Detailed information on 201 our microRNA and gene sequencing and analysis pipeline is provided in **Supplementary** 202 Methods 1. MicroRNAs and genes with overall mean expression levels greater than 15 reads 203 and expressed in at least 5% of the participants were included for further analysis, resulting in 204 a total of 415 microRNAs and 11,325 genes. Raw counts were normalized and transformed 205 using the varianceStabilizingTransformation function from DESeq2 (v1.30.1), which 206 includes a log2 transformation [18]. Mean normalized counts of sequenced microRNAs 207 ranged from 3.09 (for miR-4707-3p) to 21.34 (for miR-486-5p). As a last step, microRNA 208 and gene expression data were adjusted for sequencing batch effects by creating a linear 209 regression model, with microRNA normalized counts as the dependent variable and 210 sequencing batch as the independent variable, and extracting the model residuals.

211 **2.6 Assessment of cognitive function**

212 The neuropsychological test battery of the Rhineland Study has been described in detail 213 elsewhere [19]. Examined domains included working memory, episodic verbal memory, 214 processing speed, executive function, and crystallized intelligence. Working memory was 215 assessed with the orally performed Digit Span forward and backward task, and the touchpad-216 based Corsi block-tapping test, based on the Psychology Experiment Building Language 217 battery [20]. Episodic verbal memory was evaluated with the Auditory Verbal Learning and 218 Memory test with a list length of 15 words [21]. Assessment of processing speed was based 219 on a numbers-only trail-making test (Trail-making test A), and prosaccade latency (time 220 needed to initiate a saccade), derived from an eye movement test battery [22]. We examined 221 executive function using the antisaccade error rate (percentage of trials in which the 222 participant made a direction error) from the same battery, combined with a categorical word

223 fluency task (animals), and number-and-letters trail-making test (Trail making test B). Lastly, 224 we measured crystallized intelligence with the 37-item Mehrfachwahl-Wortschatz-225 Intelligenztest [23]. Cognitive domain performance scores were created by averaging the z-226 scores of the tests contributing to each domain. The creation of these z-scores was based on 227 data from the first 5000 participants of the Rhineland Study. Additionally, we averaged the z-228 scores for working memory, episodic verbal memory, processing speed, and executive 229 function to create a global cognition composite score. All examinations were administered in 230 the German language, following a standardized procedure by certified study technicians.

231 2.7 Image acquisition and brain segmentation

232 Participants underwent a one-hour examination protocol in 3T MRI scanners (Siemens 233 Prisma Magnetom, Erlangen, Germany) equipped with a 64-channel head-neck coil [24]. 234 During the MRI section, a T1-weighted multi-echo magnetization prepared rapid gradient 235 echo (MPRANGE) image was acquired [25]. T1-weighted images were processed with the 236 standard Freesurfer (version 6.0) recon-all pipeline [26] to obtain the brain imaging 237 phenotypes. For our analysis of MRI data, we evaluated regions relevant to cognitive aging 238 and neurodegeneration, namely mean and regional cortical thickness, and hippocampal 239 volume [27]. In addition, we evaluated total brain volume as a general indicator of brain 240 health. Regional cortical thickness was evaluated for the 31 cortical Regions of Interest 241 (ROIs) included in the Desikan–Killiany–Tourville (DKT) cortical atlas [28], and was 242 separately assessed for the left and right hemispheres.

243 **2.8 Demographic and biochemical variables**

244 Participants' age and sex were included as demographic variables. Information on

245 educational level, native language, and history of physician-diagnosed neuropsychiatric or

246 neurodegenerative disorders was based on self-reports. Educational level was determined 247 using the International Standard Classification of Education 2011 and was coded as low (lower secondary education or below), middle (upper secondary education to undergraduate 248 249 university level), and high (postgraduate university study). Native language was coded as 250 German or other. Differential blood cell count measurements (erythrocytes, nucleated 251 erythrocytes, leukocytes, and platelets) were performed at the Central Laboratory of the 252 University Hospital in Bonn, using EDTA-whole blood samples on a hematological analyzer 253 Sysmex XN9000.

254 2.9 Statistical analysis

Descriptive data were expressed as mean ± standard deviation (SD) and counts with proportions for numerical and categorical variables. To compare cognitive scores among the main analytical sample and the subsamples used for brain imaging and gene expression analyses, we used Type III Analysis of Covariance adjusting for age and sex.

259 To examine the association of microRNA expression with cognitive scores, we followed two 260 complementary methods. First, based on the guilt-by-association framework [29], we 261 assumed that microRNAs that follow similar expression patterns act jointly to form 262 biologically functional units. We utilized the Weighted Gene Co-expression Network 263 Analysis (WGCNA) method [30], to create groups of similarly expressed microRNAs (co-264 expression analysis). This allowed us to account for the correlated structure of microRNA 265 expression data, increasing our statistical power for detecting trait-related microRNAs. 266 Second, we performed a *per microRNA* analysis, meaning that we directly examined the 267 association of individual microRNAs with cognitive scores. This was done to account for 268 single microRNAs that might be strongly related to cognitive outcomes, but only weakly coexpressed with other microRNAs, in which case the grouping method would be less effective. 269

270 2.9.1 Construction of weighted gene co-expression network

271 We clustered microRNAs in *co-expression* modules using the WGCNA R package (v.1.70-3) 272 [30,31]. We chose a soft thresholding power of 7 based on scale-free topology, and we used 273 the Hybrid Dynamic Tree Cut method to identify microRNA modules, with a minimum 274 module size of 5. This resulted in 16 modules, which we refer to by randomly assigned colors 275 (green, magenta, turquoise, black, pink, yellow, brown, red, blue, greenyellow, purple, cyan, 276 salmon, lightcyan, midnightblue, tan). We then reduced the expression of all microRNAs in a 277 module to a single value (module expression). Detailed information on the application of the 278 WGCNA algorithm is provided in **Supplementary Methods 2.**

279 2.9.2 Association of module and microRNA expression with cognition

280 For the *co-expression* and *per microRNA* analyses we examined the association of module 281 and microRNA expression with cognitive scores using multiple linear regression. Firstly, we 282 converted all numeric variables to z-scores, to permit the comparability of all linear 283 regression coefficients. Then, for each module, each microRNA, and each cognitive score we 284 created a separate model including module or microRNA expression as the independent 285 variable and cognitive score as the dependent variable while adjusting for age and sex (Model 286 1: cognitive score ~ microRNA or module expression + age + sex). Additionally, we created a 287 second model that included educational level and native language as covariates. For 288 crystallized intelligence, however, we did not adjust for native language as German as a 289 native language is a prerequisite for undertaking the test (Model 2: cognitive score ~ 290 *microRNA or module expression* + *age* + *sex* + *educational level* [+ *native language*]). 291 Lastly, we performed a sensitivity analysis by excluding participants who reported a 292 physician-diagnosed neuropsychiatric or neurodegenerative disorder (i.e., dementia,

293 Parkinson's disease, multiple sclerosis, stroke, schizophrenia), and re-ran Model 1 in the294 remaining sample.

295 2.9.2.1 Replication of microRNAs previously associated with cognition and AD or MCI

296 The first part of our *per microRNA* analysis consisted of a replication analysis for *a priori* 297 selected microRNAs. This included 46 microRNAs associated with cognition in previous 298 similar studies [12–16], and 10 microRNAs consistently found to be differentially expressed 299 in the blood of AD and Mild Cognitive Impairment (MCI) patients in a recent meta-analysis 300 [17]. An overview of these studies can be found in **Supplementary Table S1**. As all of these 301 studies only examined measures of fluid intelligence, for this analysis we only included 302 cognitive scores that reflect fluid intelligence (i.e., global cognition, working memory, 303 episodic verbal memory, processing speed, and executive function). One study examined the 304 association of microRNA expression with cognition using linear regression, as well as 305 comparing expression between two cognitive performance categories [15]. For this study, we 306 included for replication microRNAs from the linear regression analysis, which presented 307 greater similarity with our own method. P values for the replication analysis were not 308 corrected for multiple testing.

309 2.9.2.2 Hypothesis-free analysis

Beyond the replication analysis, the association of microRNAs with cognition was evaluated without *a priori* hypotheses and thus we corrected for multiple testing using the Benjamini-Hochberg false discovery rate (fdr) method. Specifically, *P* values were corrected for the number of modules (n=16) for the *co-expression* analysis, and for the number of microRNAs (n=415) for the *per microRNA* analysis.

After identifying modules significantly associated with cognitive scores in the *co-expression analysis*, we also identified hub microRNAs in these modules. These were defined as

microRNAs significantly associated with the same cognitive score as the module, and highly
correlated with module expression (*high significance* and *high membership* microRNAs;

Supplementary Methods 2). Here, P values were not corrected for multiple testing, as this
was only done for the modules already significantly associated with cognitive scores. In all

321 cases, the statistical significance level was set at 0.05 (fdr \leq .05 or *P* value \leq .05).

322 2.9.3 Interaction and stratification based on age and sex

323 To examine whether age and sex modified the association of microRNAs with cognitive

324 scores, we used additional linear models, including interaction terms between microRNA

325 expression and age (Model 3: cognitive score ~ microRNA expression + age +

326 *microRNA* × age + sex), or between microRNA expression and sex (Model 4: *cognitive score*

327 \sim microRNA expression + age + sex + microRNA × sex). For microRNAs with a significant

interaction term with either age or sex, we additionally performed a stratification analysis.

329 This was done by splitting our main analytical sample based on median age in older (\geq 54

330 years) or younger (<54 years) participants, and in men or women. We then ran Model 1 again

in these age and sex strata.

332 2.9.4 Association of cognition-related microRNAs with brain MRI measures

333 MicroRNAs identified as significantly associated with cognition through the replication and 334 hypothesis-free analyses were evaluated for their association with hippocampal volume, 335 mean cortical thickness and total brain volume. MicroRNAs that were significantly 336 associated with mean cortical thickness were further evaluated for their association with 337 cortical ROI thickness. As for the association of microRNAs with cognitive scores, this was 338 done by first converting numeric variables to z-scores and then employing multivariable 339 linear regression. Brain MRI traits were included as the dependent variable and microRNA 340 expression as the independent variable while adjusting for age and sex. When the dependent

341 variable was hippocampal or total brain volume, we additionally adjusted for estimated Total

342 Intracranial Volume (eTIV), to account for differences in head size (Model: brain MRI

343 measure ~ microRNA or module expression + age + sex [+ eTIV]). The results of this analysis

344 were not corrected for multiple testing based on the *a priori* hypothesis that microRNAs

345 associated with cognition would also be associated with brain structure.

346 **2.10 MicroRNA expression in tissues**

After identifying the microRNAs significantly associated with cognition, we assessed in which tissues they were most highly expressed. For this, we used miRNATissueAtlas2, an online resource that provides data on microRNA expression in 60 human tissues, acquired post-mortem from 6 donors [32]. Using this data, we converted microRNA expression across tissues to a z-score and we calculated the median of microRNA expression for each tissue across donors.

353 **2.11 Functional genomics analysis**

354 To determine genes that could be regulated by microRNA modules in vivo, we first obtained 355 putative target genes for each microRNA using the *multimir* R package (v.1.12.0) [33]. 356 Subsequently, we examined the association between microRNA and target gene expression in 357 our partipants using linear regression, adjusting for age, sex, and blood cell counts (Model: 358 target gene expression ~ microRNA expression + age + sex + erythrocyte count + nucleated359 erythrocyte count + leukocyte count + platelet count). We kept for further analysis genes 360 whose expression was negatively associated with the expression of the targeting microRNA. 361 These genes were then used for a pathway enrichment analysis, pooling target genes of 362 microRNAs belonging to the same WGCNA module, and using the Gene Ontology: 363 Biological Processes database and the "clusterProfiler" (v. 3.18.1) R Bioconductor package

364 [34]. Semantically similar terms were collapsed *post hoc* using the *rrvgo* (v. 1.2.0) R 365 Bioconductor package [35], setting a small similarity threshold of 0.6. For detailed 366 information on the identification of target genes and functional enrichment, refer to 367 Supplementary Methods 3. We additionally examined the enrichment of target genes 368 among genes identified in a published Genome-Wide Association Study (GWAS) of general 369 cognitive function. This study identified 709 cognition-related genes, and gene expression 370 data was available for 385 of those genes in our data [36]. The enrichment analysis was done 371 by examining whether the target genes of each microRNA were overrepresented among the 372 genes identified by the GWAS using a hypergeometric test ("hypeR" R Bioconductor package, v.1.10.0). This analysis was performed for individual microRNAs and not per 373 374 module, to identify the most relevant single microRNAs. The statistical significance level fir 375 enrichment analyses was set at .05 (fdr \leq .05 or *P* value \leq .05).

All analyses were performed using the R programming environment (v. 4.1.0).

377 2.12 Data availability

The data from the Rhineland Study are not publicly available due to data protection
regulations. Access to data can be provided to scientists in accordance with the Rhineland
Study's Data Use and Access Policy. Requests for additional information or to access to the

381 Rhineland Study's datasets can be send to <u>RS-DUAC@dzne.de</u>.

382

384 3 RESULTS

385 **3.1 Participant characteristics**

In our main analytical sample (cognition dataset, n=2869 participants), the mean age was 55.01 years, (SD=14.13 years, range=30-95 years) and 56% of participants were women. The subset of participants with complete MRI data was slightly younger and had slightly higher cognitive domain scores (**Table 1**). However, when adjusted for age and sex, the cognitive domain scores did not significantly differ between the cognition dataset and its subsets (all *P* values > .1).

392 **3.2** Association of microRNAs and microRNA co-expression modules with cognition

393 3.2.1 Replication of microRNAs previously associated with cognition, AD, or MCI

394 Among the 46 microRNAs associated with cognition in previous population-based studies, 395 miR-340-5p, miR-125b-5p, mir-4732-3p and miR-92a-3p were associated with at least one 396 cognitive score in the same direction in our *per microRNA* analysis. Of note, miR-4732-3p 397 had been found in two of the previous studies [12,13] and, among these 46 microRNAs, it 398 had the strongest association with cognition in our data. Conversely, seven microRNAs were 399 significantly associated with cognitive scores in the opposite direction in our data, compared 400 to previous studies. Six of these microRNAs, miR-30e-3p, miR-342-5p, miR-574-5p, miR-401 320c, miR-215-5p, miR-320b, miR-122-5p, came from the same study by Comfort et al [13], 402 which had included older (median age: 71 years) and only male participants. The seventh 403 microRNA, miR-122-5p, had been identified in a study by Yaqub et al [12], which also 404 included older participants (median age: 70.3 years) compared to our study (Figures 1A & 405 1B). To examine whether these inconsistent findings were due to the age or sex differences in 406 the examined populations, we included the six microRNAs from Comfort et al in a sex407 stratified analysis, and all seven microRNAs in an age-stratified analysis (shown in Section
408 3.2.5).

Among the 10 microRNAs differentially expressed in AD and MCI [17], higher miR-128-3p
expression had been previously found higher in MCI patients and was associated with worse
global cognition, executive function and episodic verbal memory performance in our data
(Figure 1C).

413 *3.2.2 Hypothesis-free co-expression analysis*

414 Beyond the replication of previous studies, we performed a hypothesis-free analysis to 415 identify novel microRNA co-expression modules and hub microRNAs associated with 416 cognition. Using WGCNA, we identified 16 microRNA co-expression modules with a size 417 ranging from 5 to 129 microRNAs (Supplementary Fig. S1). Modules were named after 418 randomly assigned colors Adjusting for age and sex, and after correction for multiple testing, 419 higher expression of only one of these modules (lightcyan) was significantly associated with 420 worse episodic verbal memory (standardized ß: -0.048, 95% Confidence Interval [CI]: -0.078 421 to -0.019, fdr-corrected P value: .021, adjusted R²: 0.35). Additionally, we observed trends towards association of lower expression of another module (greenyellow) and higher 422 423 expression of three modules (salmon, turquoise and pink) with better performance across 424 most scores. However, none of these associations were significant after multiple testing 425 correction (Figure 2A). When additionally adjusting for educational level and first language, 426 increased expression of the greenyellow module became significantly associated with worse 427 executive function (standardized β: -0.045, 95% CI: -0.075 to -0.016, fdr-corrected *P* value: 428 .043, adjusted R²: 0.36). With the same adjustment, higher expression of the lightcyan 429 module remained significantly associated with worse episodic verbal memory, yet the 430 association slightly weakened (standardized B: -0.041, 95% CI: -0.070 to -0.012, fdr-

431 corrected *P* value: .097, adjusted R²: 0.39; Figure 2B). Based on these findings, we decided
432 to retain the greenyellow and lightcyan modules for further analyses, as they demonstrated
433 the strongest and most consistent associations with cognitive function.

We then identified hub microRNAs in these two modules, defined as microRNAs strongly
correlated with module expression, while being significantly associated with the same
cognitive domains as the modules (i.e., executive function for the greenyellow module and
episodic verbal memory for the lightcyan module). In the model adjusted for age and sex,
these conditions were fulfilled for four microRNAs from the greenyellow module, miR-1345p, miR-409-3p, miR-370-3p and miR-493-3p, and for two microRNAs from the lightcyan
module, miR-215-5p and miR-192-5p (Figure 2C).

441 *3.2.3 Hypothesis-free per microRNA analysis*

442 For the next step of the hypothesis-free analysis, we individually examined all microRNAs 443 measured in our study (n=415) in relation to cognitive function, regardless of co-expression 444 module. Adjusting for age and sex, we identified four microRNAs, miR-92b-3p, miR-1976, 445 miR-10401-3p and miR-4677-5p, which were significantly associated with executive 446 function after multiple testing correction. The same microRNAs were significantly associated 447 with global cognition, with the exception of miR-92b-3p, which was associated with global 448 cognition at borderline significance (Figure 2C). Results changed only slightly when 449 additionally adjusting for education and native language (Supplementary Fig. S2). Of note, 450 miR-92b-3p is closely related to miR-92a-3p, which was identified in our replication analysis 451 (Section 3.2.1). These two microRNAs belong to the same family (mir-25 family) and share 452 highly similar mature sequences [37]. Despite that, their expression levels were only 453 moderately correlated in our data (Pearson's correlation coefficient: 0.37, 95% CI: 0.34 to 454 0.40)

455 Thus, combining the results from our literature replication, as well as our *co-expression* and 456 per microRNA hypothesis-free analyses, we detected a signature of five previously identified 457 (miR-340-5p, miR-125b-5p, mir-4732-3p, miR-92a-3p, miR-128-3p) and 10 novel 458 microRNAs (miR-192-5p, miR-134-5p, miR-370-3p, miR-409-3p, miR-493-3p, miR-215-5p, 459 miR-4677-5p, miR-10401-3p, miR-1976, miR-92b-3p) that were strongly related to 460 cognition. Notably, while significant associations were primarily found with executive 461 function or episodic verbal memory scores, these 15 microRNAs were nominally associated 462 with most other cognitive scores as well (Figure 3A). Median values and distribution of the 463 expression (normalized counts) of the 15 microRNAs can be found in Supplementary Fig. **S3**. 464

465 3.2.4 Neuropsychiatric and neurodegenerative disorder sensitivity analysis

To ensure that our results were not confounded by dysregulation of microRNA expression due to neuropsychiatric or neurodegenerative disorders, we performed the same analysis after excluding participants with a self-reported physician diagnosis of dementia (n=3), Parkinson's disease (n=8), multiple sclerosis (n=13), stroke (n=48), and schizophrenia (n=2). This sensitivity analysis resulted in only slight differences in linear regression coefficients for the 16 co-expression modules and the 15 cognition-related microRNAs, without affecting statistical significance (Supplementary Fig. S4).

473 *3.2.5 Age and sex as effect modifiers*

474 Next, we examined whether the association of the microRNAs with cognition was modified
475 by age or sex. We detected significant positive interaction terms with age for the associations
476 of miR-128-5p with episodic verbal memory and global cognition, miR-125b-5p with
477 executive function and crystallized intelligence, and miR-92a-3p with working memory. Age-

478 stratified analysis confirmed that the association of these microRNAs with cognitive scores 479 was stronger in the older age group (\geq 54 years; Figure 3B). Additionally, a significant sex 480 interaction was observed for the association of miR-192-5p and miR-215-5p (lightcyan 481 module) with multiple cognitive domains, miR-4732-3p with executive function and miR-482 340-5p with crystallized intelligence. Sex-stratified analysis showed that these microRNAs 483 were more strongly associated with most cognitive domains in men. The effect modification 484 was especially pronounced for miR-215-5p. Higher expression of this microRNA was 485 associated with worse working memory and crystallized intelligence performance in the total 486 sample and among men, but with better performance in these domains among women 487 (Figure 3C).

488 Seven microRNAs, including the abovementioned miR-215-5p, were inconsistently 489 associated with cognition in our study and in previous studies by Comfort et al. and Yaqub et 490 al. [12,13] (Section 3.2.1). As these previous studies included older participants compared to 491 ours, the inconsistent associations of microRNAs with cognition might have been driven by 492 age-dependent effects. Age-stratified analysis for these microRNAs partially confirmed this 493 assumption. Specifically, for four microRNAs (miR-342-5p, miR-320b, miR-320c, miR-574-494 5p), the inconsistent association with cognition was stronger in younger participants and 495 tended towards the null in older participants (Supplementary Fig. S5A). Similarly, the study 496 by Comfort et al. included only male participants. For four of the microRNAs identified in 497 this study (miR-342-5p, miR-320b, miR-320c, miR-30e-3p) the inconsistent association with 498 cognition was stronger in women and tended towards the null in men (Supplementary Fig. 499 **S5B**). However, the assumption of sex driving the inconsistent association with cognition was 500 not confirmed for miR-215-5p. As mentioned above, higher miR-215-5p expression was 501 associated with much worse cognitive function among men in our study, but with better 502 cognitive function among the male population of Comfort et al.

503 **3.3** Association of cognition-related microRNAs with brain MRI measures

504 Next, we assessed whether the expression of the 15 microRNAs identified as associated with 505 cognition was also associated with mean cortical thickness, hippocampal volume, and total 506 brain volume. Higher expression of miR-128-3p, miR-215-5p and miR-192-5p was 507 significantly associated with a thinner cortex, and higher miR-192-5p expression was 508 additionally associated with smaller total brain volume. On the contrary, higher expression of 509 miR-4732-3p, miR-92b-3p, miR-1976 and miR-10401-3p was associated with a thicker 510 cortex. Moreover, higher miR-125b-5p expression was associated with larger left 511 hippocampal volume, which was consistent with its association with better cognitive 512 function. Surprisingly, although miR-340-5p expression was associated with worse cognitive 513 function, it was also associated with larger left hippocampal volume and, at borderline significance, a thinner cortex (Figure 3A). 514

515 ROI-specific analysis showed that the association of microRNAs with cortical thickness was 516 overall strongest in the left hemisphere, and followed similar patterns for microRNAs in the 517 same module. Specifically, the associations were strongest in the left middle temporal and 518 postcentral gyri for lightcyan module microRNAs (miR-215-5p, miR-192-5p), and in the left 519 precentral and superior temporal gyri for turquoise model microRNAs (miR-10401-3p, miR-520 1976, miR-92b-3p). For miR-4732-3p (salmon module), the associations were strongest 521 bilaterally in the precentral and superior temporal regions, and in the right paracentral region. 522 The association of miR-128-3p (purple module) with cortical thickness was overall weaker, and localized in the right middle and inferior temporal regions (Figure 4). 523

Lastly, it is worth mentioning that expression of miR-1976, miR-92b-3p, miR-128-3p and

525 miR-192-5p was significantly or borderline significantly associated with the thickness of the

526 entorhinal cortex.

527 **3.4 MicroRNA expression in tissues**

528 Using microRNATissueAtlas data, we determined that the majority of the 15 cognition-529 related microRNAs were expressed most abundantly across brain areas, such as the 530 hippocampus, medulla oblongata, cerebellum, and cortex. MicroRNAs from the lightcyan 531 module were the only exception to this, as they were expressed most abundantly in 532 gastrointestinal tract tissues. The localization of miR-92b-3p and miR-128-3p in the cortex, hinted by their association with cortical thickness, was further reinforced by the high 533 534 expression of these microRNA in the frontal lobe. Similarly, miR-125b-5p, which was 535 associated with hippocampal volume, was also highly expressed in the hippocampus (Figure

536 **5**).

537 **3.5 Functional genomics analysis**

538 3.5.1 Identification of microRNA target genes

To better understand the function of the cognition-related microRNAs, we leveraged gene 539 540 expression data, available in a subset of our study participants. In total, the 15 cognition-541 related microRNAs had 9072 putative target genes, and for 2560 of them expression of the 542 targeting microRNA was negatively associated with gene expression. The close biological 543 relation between miR-92a-3p and miR-92b-3p was corroborated by their relatively high 544 number of shared negatively associated target genes (n=382 genes). Notably, these two 545 microRNAs also shared a high number of negatively associated target genes with miR-128-546 3p (n=97). Beyond that, the 15 microRNAs had relatively few shared target genes (Supplementary Fig. S6). 547

548 3.5.2 Pathway enrichment analysis of microRNA target genes

549 We then performed a Gene Ontology functional enrichment analysis of the negatively 550 associated target genes per WGCNA module. This highlighted the distinct biological 551 functions performed by each module. For example, the greenyellow module was highly 552 enriched for "mitochondrial membrane permeability" and "mitochondrial transport", the 553 lightcyan module was highly enriched for "Wnt signaling", "cell growth" and "wound 554 healing", while the turquoise module was highly enriched for "brain development". Notably, 555 pathways highly relevant to cognition were jointly enriched for several modules. This 556 included "axon guidance", "dendrite development", "neurogenesis" and "synapse assembly" 557 for the turquoise, purple, lightcyan and blue modules. Similarly, "transforming growth factor 558 beta (TGF- β) signaling" was among the top results for the turquoise, brown, purple, lightcyan 559 and blue modules, while "memory" was enriched for the turquoise, purple, greenyellow and 560 blue modules. Moreover, "response to estradiol" was enriched for the lightcyan module 561 (Figure 6A).

562 3.5.3 MicroRNA target genes in relation to general cognitive function

To further validate the involvement of the 15 identified microRNAs in cognition, we tested the overlap between microRNA target genes and genes identified by a recent GWAS of general cognitive function. Notably, only targets of miR-92b-3p and miR-92a-3p were significantly overrepresented among the genes identified by the GWAS (**Figure 6B**).

568 4 DISCUSSION

569 In the present study, we identified 15 microRNAs associated with cognitive domains in a 570 large, general population-based cohort with a wide age range. Importantly, five of these 571 microRNAs were identified by reproducing the results of previous studies. Our subsequent 572 analyses using brain imaging and gene expression data enabled a detailed characterization of 573 identified microRNAs, providing information on the mechanisms underlying their relation to 574 cognition. Some microRNAs were associated with cortical thickness and hippocampal 575 volume, while most were highly expressed in brain tissues and regulated key neuronal 576 processes. Taken together, our large sample size, inclusion of previous studies, and analysis 577 of multimodal data increase the robustness of our findings. Additionally, our results 578 demonstrate the potential of identified microRNAs as biomarkers or therapeutic targets 579 against cognitive dysfunction.

580 MicroRNAs associated with different cognitive domains or cortical regions could be 581 investigated as blood-based biomarkers for disorders that preferentially affect these domains 582 or regions, such as AD for memory and the temporal lobe, or Frontotemporal Dementia for 583 executive function and the frontal lobe [38]. For example, miR-128-3p, which was 584 upregulated in MCI patients in a past meta-analysis, was also associated with worse cognition 585 in our study. In addition to MCI, miR-128-3p has also been dysregulated in AD [17], while 586 suppressing its expression has been found to protect against AD pathology and memory loss 587 in mice [39]. Moreover, we showed that it was associated with thickness in the temporal lobe 588 and entorhinal cortex, which are affected very early in the pathophysiology of AD [40]. Early 589 upregulation of this microRNA could indicate accelerated neurodegeneration, leading to 590 brain atrophy and cognitive dysfunction. This would make it an ideal target for detecting and 591 preventing AD-related cognitive dysfunction. However, contrary to the findings of our and

other studies, a previous population-based study found that miR-128-3p was downregulated
in participants with worse cognition [15]. Thus, further investigations are needed to
determine its exact association with cognition.

595 Several of the identified microRNAs were associated with cortical thickness in regions 596 involved in various cognitive processes. This corroborates the importance of these 597 microRNAs for cognition and could indicate that their relation with cognition is mediated by 598 the modulation of brain structure. For example, we determined that microRNAs were 599 strongly associated with cortical thickness in the precentral, superior temporal (miR-10401-600 3p, miR-1976, miR-92b-3p, miR-4732-3p), postcentral, and middle temporal regions (miR-601 215-5p, miR-192-5p, miR-128-3p). The superior and middle temporal regions are implicated 602 in a host of cognitive tasks, including audiovisual processing and integration [41], declarative 603 memory, and language [42]. The localization in the left postcentral and precentral gyri 604 (primary motor and somatosensory cortex) might implicate these microRNAs in normal, non-605 neurodegenerative brain aging, as age-related atrophy is increased in these areas [27]. 606 Moreover, recent evidence supports the involvement of the sensorimotor region in higher 607 cognitive functions, such as attention and learning for the primary motor cortex [43], or 608 associative episodic memory for the somatosensory cortex [44]. Lastly, miR-340-5p and 609 miR-125b-5p were associated with the volume of the hippocampus, perhaps the most 610 established region in relation to memory and AD [45].

611 Our functional genomics analysis determined that most of the 15 microRNAs jointly regulate 612 processes intrinsically related to cognition, such as memory, axon guidance, dendrite 613 development, neurogenesis and synapse assembly. In addition, microRNAs from five 614 modules jointly regulated TGF- β signaling, which plays an important role in neuronal 615 development and neuroprotection in neurodegeneration [46,47]. Of note, this included miR-

616 192-5p, which has been found to directly affect cognitive function through the modulation of 617 TGF- β signaling in a mouse model of depression [48]. Despite this overlap in enrichment 618 results, the microRNAs in each module shared few common target genes, suggesting that 619 they are involved in different, complementary stages of the abovementioned processes. These 620 findings point towards possible interventions for the prevention or treatment of cognitive 621 dysfunction. For example, miR-192-5p and miR-215-5p were associated with temporal lobe 622 thickness and episodic verbal memory. The target genes of these microRNAs were related to 623 WNT signaling, especially known for its involvement in synaptic plasticity and AD 624 pathology [49]. This interaction with WNT signaling, which for miR-192-5p has also been 625 observed experimentally [50], could be further investigated as a means of preventing cortical 626 atrophy and cognitive dysfunction in aging or AD. Besides microRNA-regulated pathways, 627 the functional genomics analysis particularly highlighted the importance of the closely related 628 miR-92a-3p and miR-92b-3p. A significant proportion of the target genes of these 629 microRNAs have been linked to cognition in a previous GWAS [36]. Moreover, miR-92b-3p 630 was associated with cortical thickness and was highly expressed in the cortex and 631 hippocampus. Importantly, both microRNAs have been previously shown to exert 632 neuroprotective effects [51–54].

633 Due to the nature of our data and analysis, we cannot conclude causality of the observed 634 associations. However, some of the identified microRNAs have been causally linked to 635 cognition or brain health in past experimental studies. Among them, miR-134-5p has been 636 most extensively studied as a regulator of synaptic plasticity, dendritogenesis, long-term 637 potentiation, and neuronal injury [55–59]. Aberrant regulation of these processes by miR-638 134-5p can lead to cognitive deficits [57,60,61]. Similarly, miR-409-3p has been found to 639 induce cognitive deficits through impairment of neuronal viability [62], while miR-192-5p 640 mediates the effects on cognitive function of exercise [63] and, as mentioned above,

- 641 depression through TFG- β [48]. Moreover, miR-340-5p has been found to exert
- 642 neuroprotective effects [64], while miR-493-3p, miR-1976 and miR-125b-5p worsen the
- 643 neurotoxic effects of stroke [65], Parkinson's disease [66], and AD [67].

644 Some of our findings were unexpected and suggest novel research questions regarding the 645 relation of microRNAs with brain function. We identified seven microRNAs that were 646 associated with cognition in opposite directions in our data compared to two previous studies 647 [12,13]. We showed that this could be due to the differences in the examined populations. 648 Specifically, for five out of seven microRNAs, the inconsistent association with cognition 649 largely disappeared in subsets of our population that matched the age and sex composition of 650 the previous studies. However, these inconsistent results illustrate that further validation is 651 needed to determine the precise relation of these microRNAs with cognition. Moreover, three 652 microRNAs (miR-128-3p, miR-92a-3p, miR-125b-5p) showed a stronger association with 653 cognition in older participants. This could be attributed to their interaction with mechanisms 654 of aging or neurodegeneration. For example, all three microRNAs have been implicated in 655 AD pathogenesis [39,68,69]. Similarly, four microRNAs (miR-215-5p, miR-192-5p, miR-656 4732-3p, miR-340-5p) were associated with cognitive domain scores in a sex-dependent 657 manner. This could be explained by an interaction of these microRNAs with sex hormone 658 signaling, which is known to impact cognition [70]. In support of this, our functional 659 enrichment results showed that miR-215-5p and miR-192-5p might regulate cellular 660 responses to estradiol. For miR-192-5p, an interaction with estrogen receptors has also been 661 observed experimentally [71]. However, further research is needed to define the mechanisms 662 behind these age- and sex-dependent effects. Lastly, we observed an unexpected association 663 of increased miR-340-5p expression with worse executive function and lower mean cortical 664 thickness, but higher hippocampal volume. The consensus of past experimental studies 665 supports the association of miR-340-5p with hippocampal volume, as it has been shown to

have neuroprotective effects [64,72,73]. These conflicting findings could imply that this
microRNA might have pleiotropic, location-dependent functions. Thus, its action might be
neuroprotective in the hippocampus, but neurotoxic in the cortex, resulting in a net negative
association with cognition. However, further investigation is required to test this assumption.

670 Our study has both strengths and limitations. As mentioned, our large sample size, wide age 671 range, and inclusion of previous similar studies increase the reliability of our findings. 672 Moreover, we were able to comprehensively characterize microRNAs of interest and draw 673 conclusions as to their function, by combining an extensive neuropsychological test battery, 674 individual-level gene expression data, detailed brain imaging measures and publicly available 675 resources. However, our study is not without drawbacks. Our use of WGCNA is based on the 676 assumption that similarly expressed microRNAs have shared biological functions, a principle 677 that has been previously contested [74]. Furthermore, as is common in population-based 678 studies, our study participants were all residents of the same geographical region, limiting the 679 generalizability of our findings. Lastly, when comparing our results to previous similar 680 studies, there was a relatively small overlap and even some conflicting findings. This 681 illustrates the necessity for the validation of study results and for the standardization of 682 microRNA sampling and measurement methods.

In conclusion, here we identified a signature of five previously identified and 10 novel microRNAs associated with cognitive function across different domains. Some of these microRNAs were concurrently related to cortical thickness and hippocampal volume, suggesting that they regulate cognitive processes through modulation of brain structure. Our functional genomics analysis demonstrated the importance of the identified microRNAs for a number of neuronal functions and emphasized miR-92a-3p and miR-92b-3p, which were abundant in cortical tissue and regulated cognition-related genes. In the future, the identified

- 690 microRNAs could be leveraged to develop signatures for the early detection of dementia in
- 691 clinical or research settings. Moreover, future interventional studies could utilize them for the
- 692 prevention of cognitive dysfunction due to aging or neurodegeneration.

693

694 Abbreviations

- AD, Alzheimer's Disease; ROIs, Regions Of Interest; eTIV, estimated Total Intracranial
- 696 Volume; DKT, Desikan-Killiany-Tourville; SD, Standard Deviation; WGCNA, Weighted
- 697 Gene Co-Expression Analysis; fdr, false discovery rate; GWAS, Genome-Wide Association
- 698 Study; MCI, Mild Cognitive Impairment; CI, Confidence Interval; HCV, Hippocampal
- 699 Volume; TGF- β , transforming growth factor beta

700

702 Acknowledgements

- 703 We wish to thank all participants of the Rhineland Study and the study personnel that was
- 704 involved in data collection. Additionally, we would like to thank Dr. Dan Liu for her
- 705 feedback on a previous version of this manuscript.

706 Sources of Funding

- 707 This work was further supported by the Federal Ministry of Education and Research grant
- 708 [FKZ: 01KX2230] with the title "PreBeDem Mit Prävention und Behandlung gegen
- 709 Demenz" and the Helmholtz Association under the 2023 Innovation Pool. The Rhineland
- 710 Study is funded by the German Center for Neurodegenerative Diseases (DZNE). Andre
- 711 Fischer received funding from the DFG priority program 1738, SFB1286, SFB 1002, by
- 712 Germany's Excellence Strategy EXC 2067/1 390729940, the ERA-Net Neuron project
- 713 EPINEURODEVO and the JPND project EPI-3E.

715 **References**

716	[1]	Chowdhary N, Barbui C, Anstey KJ, Kivipelto M, Barbera M, Peters R, et al.
717		Reducing the risk of cognitive decline and dementia: WHO recommendations. Front
718		Neurol 2021;12:765584. https://doi.org/10.3389/fneur.2021.765584.
719	[2]	Morley JE, Morris JC, Berg-Weger M, Borson S, Carpenter BD, Del Campo N, et al.
720		Brain health: the importance of recognizing cognitive impairment: an IAGG
721		consensus conference. J Am Med Dir Assoc 2015;16:731–9.
722		https://doi.org/10.1016/j.jamda.2015.06.017.
723	[3]	Howieson D. Current limitations of neuropsychological tests and assessment
724		procedures. Clin Neuropsychol 2019;33:200-8.
725		https://doi.org/10.1080/13854046.2018.1552762.
726	[4]	Whelan R, Barbey FM, Cominetti MR, Gillan CM, Rosická AM. Developments in
727		scalable strategies for detecting early markers of cognitive decline. Transl Psychiatry
728		2022;12:473. https://doi.org/10.1038/s41398-022-02237-w.
729	[5]	Fiocco AJ, Krieger L, D'Amico D, Parrott MD, Laurin D, Gaudreau P, et al. A
730		systematic review of existing peripheral biomarkers of cognitive aging: Is there
731		enough evidence for biomarker proxies in behavioral modification interventions?: An
732		initiative in association with the nutrition, exercise and lifestyle team of the Canadian
733		Consortium on Neurodegeneration in Aging. Ageing Res Rev 2019;52:72–119.
734		https://doi.org/10.1016/j.arr.2019.04.008.
735	[6]	Mehta K, Mohebbi M, Pasco JA, Williams LJ, Sui SX, Walder K, et al. A plasma
736		protein signature associated with cognitive function in men without severe cognitive

737		impairment. Alzheimers Res Ther 2023;15:148. https://doi.org/10.1186/s13195-023-
738		01294-7.
739	[7]	Salta E, De Strooper B. Non-coding RNAs with essential roles in neurodegenerative
740		disorders. Lancet Neurol 2012;11:189-200. https://doi.org/10.1016/S1474-
741		4422(11)70286-1.
742	[8]	Woldemichael BT, Mansuy IM. Micro-RNAs in cognition and cognitive disorders:
743		Potential for novel biomarkers and therapeutics. Biochem Pharmacol 2016;104:1-7.
744		https://doi.org/10.1016/j.bcp.2015.11.021.
745	[9]	Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell
746		2004;116:281-97. https://doi.org/10.1016/s0092-8674(04)00045-5.
747	[10]	Juźwik CA, S Drake S, Zhang Y, Paradis-Isler N, Sylvester A, Amar-Zifkin A, et al.
748		microRNA dysregulation in neurodegenerative diseases: A systematic review. Prog
749		Neurobiol 2019;182:101664. https://doi.org/10.1016/j.pneurobio.2019.101664.
750	[11]	Walgrave H, Zhou L, De Strooper B, Salta E. The promise of microRNA-based
751		therapies in Alzheimer's disease: challenges and perspectives. Mol Neurodegener
752		2021;16:76. https://doi.org/10.1186/s13024-021-00496-7.
753	[12]	Yaqub A, Mens MMJ, Klap JM, Weverling GJ, Klatser P, Brakenhoff JPJ, et al.
754		Genome-wide profiling of circulatory microRNAs associated with cognition and
755		dementia. Alzheimers Dement 2022. https://doi.org/10.1002/alz.12752.
756	[13]	Comfort N, Wu H, De Hoff P, Vuppala A, Vokonas PS, Spiro A, et al. Extracellular
757		microRNA and cognitive function in a prospective cohort of older men: The Veterans

758 Affairs Normative Aging Study. Aging (Albany NY) 2022;14:6859–86.

- 759 https://doi.org/10.18632/aging.204268.
- 760 [14] Van der Auwera S, Garvert L, Ameling S, Völzke H, Nauck M, Völker U, et al. The
- 761 interplay between micro RNAs and genetic liability to Alzheimer's Disease on
- memory trajectories in the general population. Psychiatry Res 2023;323:115141.
- 763 https://doi.org/10.1016/j.psychres.2023.115141.
- 764 [15] Sadlon A, Takousis P, Evangelou E, Prokopenko I, Alexopoulos P, Udeh-Momoh
- 765 CM, et al. Association of Blood MicroRNA Expression and Polymorphisms with
- 766 Cognitive and Biomarker Changes in Older Adults. J Prev Alzheimers Dis
- 767 2024;11:230–40. https://doi.org/10.14283/jpad.2023.99.
- [16] Islam MR, Kaurani L, Berulava T, Heilbronner U, Budde M, Centeno TP, et al. A
 microRNA signature that correlates with cognition and is a target against cognitive
 decline. EMBO Mol Med 2021;13:e13659.
- 771 https://doi.org/10.15252/emmm.202013659.
- Yoon S, Kim SE, Ko Y, Jeong GH, Lee KH, Lee J, et al. Differential expression of
 MicroRNAs in Alzheimer's disease: a systematic review and meta-analysis. Mol
 Psychiatry 2022;27:2405–13. https://doi.org/10.1038/s41380-022-01476-z.
- [18] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion
 for RNA-seq data with DESeq2. Genome Biol 2014;15:550.
- 777 https://doi.org/10.1186/s13059-014-0550-8.

778	[19]	Coors A, Breteler MMB, Ettinger U. Processing speed, but not working memory or
779		global cognition, is associated with pupil diameter during fixation. Psychophysiology
780		2022;59:e14089. https://doi.org/10.1111/psyp.14089.
781	[20]	Mueller ST, Piper BJ. The psychology experiment building language (PEBL) and
782		PEBL test battery. J Neurosci Methods 2014;222:250-9.
783		https://doi.org/10.1016/j.jneumeth.2013.10.024.
784	[21]	Boenniger MM, Staerk C, Coors A, Huijbers W, Ettinger U, Breteler MMB. Ten
785		German versions of Rey's auditory verbal learning test: Age and sex effects in 4,000
786		adults of the Rhineland Study. J Clin Exp Neuropsychol 2021;43:637-53.
787		https://doi.org/10.1080/13803395.2021.1984398.
788	[22]	Coors A, Merten N, Ward DD, Schmid M, Breteler MMB, Ettinger U. Strong age but
789		weak sex effects in eye movement performance in the general adult population:
790		Evidence from the Rhineland Study. Vision Res 2021;178:124-33.
791		https://doi.org/10.1016/j.visres.2020.10.004.
792	[23]	Lehr S. Mehrfachwahl-Wortschatz-Intelligenztest: MWT-B . Spitta GmbH; 2005.
793	[24]	Lohner V, Enkirch SJ, Hattingen E, Stöcker T, Breteler MMB. Safety of Tattoos,
794		Permanent Make-Up, and Medical Implants in Population-Based 3T Magnetic
795		Resonance Brain Imaging: The Rhineland Study. Front Neurol 2022;13:795573.
796		https://doi.org/10.3389/fneur.2022.795573.
797	[25]	van der Kouwe AJW, Benner T, Salat DH, Fischl B. Brain morphometry with
798		multiecho MPRAGE. Neuroimage 2008;40:559–69.
799		https://doi.org/10.1016/j.neuroimage.2007.12.025.

- 800 [26] Fischl B. FreeSurfer. Neuroimage 2012;62:774–81.
- 801 https://doi.org/10.1016/j.neuroimage.2012.01.021.
- 802 [27] Pini L, Pievani M, Bocchetta M, Altomare D, Bosco P, Cavedo E, et al. Brain atrophy
- in Alzheimer's Disease and aging. Ageing Res Rev 2016;30:25–48.
- 804 https://doi.org/10.1016/j.arr.2016.01.002.
- Klein A, Tourville J. 101 labeled brain images and a consistent human cortical
 labeling protocol. Front Neurosci 2012;6:171.
- 807 https://doi.org/10.3389/fnins.2012.00171.
- 808 [29] Wolfe CJ, Kohane IS, Butte AJ. Systematic survey reveals general applicability of
 809 "guilt-by-association" within gene coexpression networks. BMC Bioinformatics
 810 2005;6:227. https://doi.org/10.1186/1471-2105-6-227.
- 811 [30] Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network
- 812 analysis. BMC Bioinformatics 2008;9:559. https://doi.org/10.1186/1471-2105-9-559.
- 813 [31] Langfelder P, Horvath S. Fast R functions for robust correlations and hierarchical
- 814 clustering. J Stat Softw 2012;46. https://doi.org/10.18637/jss.v046.i11.
- 815 [32] Keller A, Gröger L, Tschernig T, Solomon J, Laham O, Schaum N, et al.
- 816 miRNATissueAtlas2: an update to the human miRNA tissue atlas. Nucleic Acids Res
- 817 2022;50:D211–21. https://doi.org/10.1093/nar/gkab808.
- 818 [33] Ru Y, Kechris KJ, Tabakoff B, Hoffman P, Radcliffe RA, Bowler R, et al. The
- 819 multiMiR R package and database: integration of microRNA-target interactions along
- 820 with their disease and drug associations. Nucleic Acids Res 2014;42:e133.
- 821 https://doi.org/10.1093/nar/gku631.

822	[34]	Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal
823		enrichment tool for interpreting omics data. Innovation (Camb) 2021;2:100141.
824		https://doi.org/10.1016/j.xinn.2021.100141.
825	[35]	Sayols S. rrvgo: a Bioconductor package to reduce and visualize Gene Ontology
826		terms. Bioconductor; 2020.
827	[36]	Davies G, Lam M, Harris SE, Trampush JW, Luciano M, Hill WD, et al. Study of
828		300,486 individuals identifies 148 independent genetic loci influencing general
829		cognitive function. Nat Commun 2018;9:2098. https://doi.org/10.1038/s41467-018-
830		04362-x.
831	[37]	Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences
832		to function. Nucleic Acids Res 2019;47:D155-62.
833		https://doi.org/10.1093/nar/gky1141.
834	[38]	Trojsi F, Christidi F, Migliaccio R, Santamaría-García H, Santangelo G. Behavioural
835		and cognitive changes in neurodegenerative diseases and brain injury. Behav Neurol
836		2018;2018:4935915. https://doi.org/10.1155/2018/4935915.
837	[39]	Liu Y, Zhang Y, Liu P, Bai H, Li X, Xiao J, et al. MicroRNA-128 knockout inhibits
838		the development of Alzheimer's disease by targeting PPAR γ in mouse models. Eur J
839		Pharmacol 2019;843:134-44. https://doi.org/10.1016/j.ejphar.2018.11.004.
840	[40]	Chandra A, Dervenoulas G, Politis M, Alzheimer's Disease Neuroimaging Initiative.
841		Magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment. J
842		Neurol 2019;266:1293-302. https://doi.org/10.1007/s00415-018-9016-3.

- 843 [41] Hein G, Knight RT. Superior temporal sulcus--It's my area: or is it? J Cogn Neurosci
 844 2008;20:2125–36. https://doi.org/10.1162/jocn.2008.20148.
- 845 [42] Roger E, Banjac S, Thiebaut de Schotten M, Baciu M. Missing links: The functional
- 846 unification of language and memory (LUM). Neurosci Biobehav Rev
- 847 2022;133:104489. https://doi.org/10.1016/j.neubiorev.2021.12.012.
- 848 [43] Bhattacharjee S, Kashyap R, Abualait T, Annabel Chen S-H, Yoo W-K, Bashir S.
- 849 The role of primary motor cortex: more than movement execution. J Mot Behav

850 2021;53:258–74. https://doi.org/10.1080/00222895.2020.1738992.

- 851 [44] Summerfield C, Greene M, Wager T, Egner T, Hirsch J, Mangels J. Neocortical
- connectivity during episodic memory formation. PLoS Biol 2006;4:e128.

853 https://doi.org/10.1371/journal.pbio.0040128.

- [45] Petersen RC, Jack CR, Xu YC, Waring SC, O'Brien PC, Smith GE, et al. Memory
 and MRI-based hippocampal volumes in aging and AD. Neurology 2000;54:581–7.
 https://doi.org/10.1212/wnl.54.3.581.
- 857 [46] Meyers EA, Kessler JA. TGF-β Family Signaling in Neural and Neuronal
- 858 Differentiation, Development, and Function. Cold Spring Harb Perspect Biol 2017;9.
- 859 https://doi.org/10.1101/cshperspect.a022244.
- 860 [47] Dobolyi A, Vincze C, Pál G, Lovas G. The neuroprotective functions of transforming
 861 growth factor beta proteins. Int J Mol Sci 2012;13:8219–58.
- 862 https://doi.org/10.3390/ijms13078219.
- 863 [48] Tang C-Z, Yang J-T, Liu Q-H, Wang Y-R, Wang W-S. Up-regulated miR-192-5p
- 864 expression rescues cognitive impairment and restores neural function in mice with

865		depression via the Fbln2-mediated TGF- β 1 signaling pathway. FASEB J
866		2019;33:606-18. https://doi.org/10.1096/fj.201800210RR.
867	[49]	Palomer E, Buechler J, Salinas PC. Wnt signaling deregulation in the aging and
868		alzheimer's brain. Front Cell Neurosci 2019;13:227.
869		https://doi.org/10.3389/fncel.2019.00227.
870	[50]	Pan Y, Sun Y, Liu Z, Zhang C. miR-192-5p upregulation mediates the suppression of
871		curcumin in human NSCLC cell proliferation, migration and invasion by targeting
872		c-Myc and inactivating the Wnt/ β -catenin signaling pathway. Mol Med Report
873		2020;22:1594-604. https://doi.org/10.3892/mmr.2020.11213.
874	[51]	Winkler I, Engler JB, Vieira V, Bauer S, Liu Y-H, Di Liberto G, et al. MicroRNA-
875		92a-CPEB3 axis protects neurons against inflammatory neurodegeneration. Sci Adv
876		2023;9:eadi6855. https://doi.org/10.1126/sciadv.adi6855.
877	[52]	Liu E, Sun H, Wu J, Kuang Y. MiR-92b-3p regulates oxygen and glucose
878		deprivation-reperfusion-mediated apoptosis and inflammation by targeting TRAF3 in
879		PC12 cells. Exp Physiol 2020;105:1792-801. https://doi.org/10.1113/EP088708.
880	[53]	Shen J, Li G, Zhu Y, Xu Q, Zhou H, Xu K, et al. Foxo1-induced miR-92b down-
881		regulation promotes blood-brain barrier damage after ischaemic stroke by targeting
882		NOX4. J Cell Mol Med 2021;25:5269-82. https://doi.org/10.1111/jcmm.16537.
883	[54]	Hu Z-Y, Yang Z-B, Zhang R, Luo X-J, Peng J. The Protective Effect of Vitexin
884		Compound B-1 on Rat Cerebral I/R Injury through a Mechanism Involving
885		Modulation of miR-92b/NOX4 Pathway. CNS Neurol Disord Drug Targets
886		2023;22:137-47. https://doi.org/10.2174/1871527321666220324115848.

887	[55]	Wang G, An T, Lei C, Zhu X, Yang L, Zhang L, et al. Antidepressant-like effect of
888		ginsenoside Rb1 on potentiating synaptic plasticity via the miR-134-mediated BDNF
889		signaling pathway in a mouse model of chronic stress-induced depression. J Ginseng
890		Res 2022;46:376–86. https://doi.org/10.1016/j.jgr.2021.03.005.
891	[56]	Wang G, Liu Y, Zhu X, Lin K, Li M, Wu Z, et al. Knockdown of miRNA-134-5p
892		rescues dendritic deficits by promoting AMPK-mediated mitophagy in a mouse model
893		of depression. Neuropharmacology 2022;214:109154.
894		https://doi.org/10.1016/j.neuropharm.2022.109154.
895	[57]	Bicker S, Lackinger M, Weiß K, Schratt G. MicroRNA-132, -134, and -138: a
896		microRNA troika rules in neuronal dendrites. Cell Mol Life Sci 2014;71:3987-4005.
897		https://doi.org/10.1007/s00018-014-1671-7.
898	[58]	Baby N, Alagappan N, Dheen ST, Sajikumar S. MicroRNA-134-5p inhibition rescues
898 899	[58]	Baby N, Alagappan N, Dheen ST, Sajikumar S. MicroRNA-134-5p inhibition rescues long-term plasticity and synaptic tagging/capture in an $A\beta(1-42)$ -induced model of
898 899 900	[58]	Baby N, Alagappan N, Dheen ST, Sajikumar S. MicroRNA-134-5p inhibition rescues long-term plasticity and synaptic tagging/capture in an $A\beta(1-42)$ -induced model of Alzheimer's disease. Aging Cell 2020;19:e13046. https://doi.org/10.1111/acel.13046.
898 899 900 901	[58] [59]	Baby N, Alagappan N, Dheen ST, Sajikumar S. MicroRNA-134-5p inhibition rescues long-term plasticity and synaptic tagging/capture in an Aβ(1-42)-induced model of Alzheimer's disease. Aging Cell 2020;19:e13046. https://doi.org/10.1111/acel.13046. Wang C, Zhang H, Li J. LncRNA JHDM1D-AS1 Suppresses MPP + -Induced
898899900901902	[58]	Baby N, Alagappan N, Dheen ST, Sajikumar S. MicroRNA-134-5p inhibition rescues long-term plasticity and synaptic tagging/capture in an Aβ(1-42)-induced model of Alzheimer's disease. Aging Cell 2020;19:e13046. https://doi.org/10.1111/acel.13046. Wang C, Zhang H, Li J. LncRNA JHDM1D-AS1 Suppresses MPP + -Induced Neuronal Injury in Parkinson's Disease via miR-134-5p/PIK3R3 Axis. Neurotox Res
 898 899 900 901 902 903 	[58]	Baby N, Alagappan N, Dheen ST, Sajikumar S. MicroRNA-134-5p inhibition rescues long-term plasticity and synaptic tagging/capture in an Aβ(1-42)-induced model of Alzheimer's disease. Aging Cell 2020;19:e13046. https://doi.org/10.1111/acel.13046. Wang C, Zhang H, Li J. LncRNA JHDM1D-AS1 Suppresses MPP + -Induced Neuronal Injury in Parkinson's Disease via miR-134-5p/PIK3R3 Axis. Neurotox Res 2021;39:1771–81. https://doi.org/10.1007/s12640-021-00437-8.
 898 899 900 901 902 903 904 	[58] [59]	Baby N, Alagappan N, Dheen ST, Sajikumar S. MicroRNA-134-5p inhibition rescues long-term plasticity and synaptic tagging/capture in an Aβ(1-42)-induced model of Alzheimer's disease. Aging Cell 2020;19:e13046. https://doi.org/10.1111/acel.13046. Wang C, Zhang H, Li J. LncRNA JHDM1D-AS1 Suppresses MPP + -Induced Neuronal Injury in Parkinson's Disease via miR-134-5p/PIK3R3 Axis. Neurotox Res 2021;39:1771–81. https://doi.org/10.1007/s12640-021-00437-8. Shen J, Xu L, Qu C, Sun H, Zhang J. Resveratrol prevents cognitive deficits induced
 898 899 900 901 902 903 904 905 	[58] [59]	Baby N, Alagappan N, Dheen ST, Sajikumar S. MicroRNA-134-5p inhibition rescues long-term plasticity and synaptic tagging/capture in an Aβ(1-42)-induced model of Alzheimer's disease. Aging Cell 2020;19:e13046. https://doi.org/10.1111/acel.13046. Wang C, Zhang H, Li J. LncRNA JHDM1D-AS1 Suppresses MPP + -Induced Neuronal Injury in Parkinson's Disease via miR-134-5p/PIK3R3 Axis. Neurotox Res 2021;39:1771–81. https://doi.org/10.1007/s12640-021-00437-8. Shen J, Xu L, Qu C, Sun H, Zhang J. Resveratrol prevents cognitive deficits induced by chronic unpredictable mild stress: Sirt1/miR-134 signalling pathway regulates
 898 899 900 901 902 903 904 905 906 	[58] [59]	Baby N, Alagappan N, Dheen ST, Sajikumar S. MicroRNA-134-5p inhibition rescues long-term plasticity and synaptic tagging/capture in an Aβ(1-42)-induced model of Alzheimer's disease. Aging Cell 2020;19:e13046. https://doi.org/10.1111/acel.13046. Wang C, Zhang H, Li J. LncRNA JHDM1D-AS1 Suppresses MPP + -Induced Neuronal Injury in Parkinson's Disease via miR-134-5p/PIK3R3 Axis. Neurotox Res 2021;39:1771–81. https://doi.org/10.1007/s12640-021-00437-8. Shen J, Xu L, Qu C, Sun H, Zhang J. Resveratrol prevents cognitive deficits induced by chronic unpredictable mild stress: Sirt1/miR-134 signalling pathway regulates CREB/BDNF expression in hippocampus in vivo and in vitro. Behav Brain Res

908	[61]	Liu X, Zhang R, Wu Z, Si W, Ren Z, Zhang S, et al. miR-134-5p/Foxp2/Syn1 is
909		involved in cognitive impairment in an early vascular dementia rat model. Int J Mol
910		Med 2019;44:1729–40. https://doi.org/10.3892/ijmm.2019.4331.
911	[62]	Wu T, Tang C, Fan J, Tao J. Administration of rTMS Alleviates Stroke-Induced
912		Cognitive Deficits by Modulating miR-409-3p/CTRP3/AMPK/Sirt1 Axis. J Mol
913		Neurosci 2022;72:507–15. https://doi.org/10.1007/s12031-021-01924-5.
914	[63]	Qin Z, Han X, Ran J, Guo S, Lv L. Exercise-Mediated Alteration of miR-192-5p Is
915		Associated with Cognitive Improvement in Alzheimer's Disease.
916		Neuroimmunomodulation 2022;29:36-43. https://doi.org/10.1159/000516928.
917	[64]	He G, Ni H, Wang K, Gao H, Li Y, Gu J, et al. Dexmedetomidine attenuates the
918		neuroinflammation and cognitive dysfunction in aged mice by targeting the
919		SNHG14/miR-340/NF-κB axis. Biomed Rep 2023;19:100.
920		https://doi.org/10.3892/br.2023.1682.
921	[65]	Li Q, He Q, Baral S, Mao L, Li Y, Jin H, et al. MicroRNA-493 regulates
922		angiogenesis in a rat model of ischemic stroke by targeting MIF. FEBS J
923		2016;283:1720-33. https://doi.org/10.1111/febs.13697.
924	[66]	Qiu F, Wu Y, Xie G, Cao H, Du M, Jiang H. MiRNA-1976 Regulates the Apoptosis
925		of Dopaminergic Neurons by Targeting the PINK1 Gene. J Integr Neurosci
926		2023;22:45. https://doi.org/10.31083/j.jin2202045.
927	[67]	Banzhaf-Strathmann J, Benito E, May S, Arzberger T, Tahirovic S, Kretzschmar H,
928		et al. MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in

- 929 Alzheimer's disease. EMBO J 2014;33:1667–80.
- 930 https://doi.org/10.15252/embj.201387576.
- 931 [68] Li X, Wang Z, Tan L, Wang Y, Lu C, Chen R, et al. Correcting miR92a-vGAT-
- 932 Mediated GABAergic Dysfunctions Rescues Human Tau-Induced Anxiety in Mice.

933 Mol Ther 2017;25:140–52. https://doi.org/10.1016/j.ymthe.2016.10.010.

234 [69] Zhang L, Dong H, Si Y, Wu N, Cao H, Mei B, et al. miR-125b promotes tau

phosphorylation by targeting the neural cell adhesion molecule in neuropathological

936 progression. Neurobiol Aging 2019;73:41–9.

- 937 https://doi.org/10.1016/j.neurobiolaging.2018.09.011.
- 938 [70] Itoh N, Itoh Y, Meyer CE, Suen TT, Cortez-Delgado D, Rivera Lomeli M, et al.

Estrogen receptor beta in astrocytes modulates cognitive function in mid-age female
mice. Nat Commun 2023;14:6044. https://doi.org/10.1038/s41467-023-41723-7.

- 941 [71] Kim YS, Park SJ, Lee YS, Kong HK, Park JH. miRNAs involved in LY6K and
- 942 estrogen receptor α contribute to tamoxifen-susceptibility in breast cancer. Oncotarget
 943 2016;7:42261–73. https://doi.org/10.18632/oncotarget.9950.
- 944 [72] Tu X, Zhang H, Chen S, Ding Y-H, Wu X, Liang R, et al. LncRNA CEBPA-AS1

945 alleviates cerebral ischemia-reperfusion injury by sponging miR-340-5p regulating

- 946 APPL1/LKB1/AMPK pathway. FASEB J 2022;36:e22075.
- 947 https://doi.org/10.1096/fj.202100826RR.
- 948 [73] Tan X, Luo Y, Pi D, Xia L, Li Z, Tu Q. MiR-340 Reduces the Accumulation of
 949 Amyloid-β Through Targeting BACE1 (β-site Amyloid Precursor Protein Cleaving

950		Enzyme 1) in Alzheimer's Disease. Curr Neurovasc Res 2020;17:86-92.
951		https://doi.org/10.2174/1567202617666200117103931.
952	[74]	Gillis J, Pavlidis P. "Guilt by association" is the exception rather than the rule in gene
953		networks. PLoS Comput Biol 2012;8:e1002444.
954		https://doi.org/10.1371/journal.pcbi.1002444.
955	[75]	Mowinckel AM, Vidal-Piñeiro D. Visualization of brain statistics with R packages
956		ggseg and ggseg3d. Advances in Methods and Practices in Psychological Science

957 2020;3:466–83. https://doi.org/10.1177/2515245920928009.

Variable **Participants with complete** Participants with complete cognitive Participants with complete cognitive cognitive examination and examination, microRNA expression, examination, microRNA expression, microRNA expression data, and brain MRI data, and gene expression data, $N = 2045^{\dagger, \ddagger}$ $N = 2138 \ddagger$ N = 2869 * 55.01(14.13) 54.31(13.90) 54.99 (14.18) Age (years), mean (SD) Sex, n (%) Female 1595 (56%) 1149 (56%) 1173 (55%) Male 1274 (44%) 896 (44%) 965 (45%) Global cognition (z-0.01 (0.64) 0.05(0.62)0.01 (0.63) score), mean (SD)[¶] Executive function (z-0.02 (0.73) -0.02(0.75)-0.03(0.75)score), mean (SD)[¶] Working memory (z-0.00 (0.71) -0.01 (0.72) 0.03(0.71)score), mean (SD)[¶] Ep. verbal memory 0.06 (0.96) 0.11 (0.93) 0.04 (0.96) (z-score), mean (SD)[¶] Processing speed (z-0.02 (0.83) 0.06 (0.82) 0.03(0.83)score), mean (SD)[¶] Crystalized 0.02 (0.96) 0.02 (0.96) 0.06 (0.93) Intelligence (z-score), mean (SD) ¶ First language, n (%) 2682 (94%) 1914 (94%) German 2006 (94%) Other 182 (6.4%) 130 (6.4%) 129 (6.0%)

Table 1: Study participant characteristics

Educational level, n (%)			
Low	55 (1.9%)	34 (1.7%)	34 (1.6%)
Middle	1248 (44%)	844 (42%)	928 (44%)
High	1543 (54%)	1152 (57%)	1155 (55%)
Left hippocampal volume (mm ³), mean (SD)	-	3.89×10 ³ (0.46×10 ³)	3.88×10 ³ (0.46×10 ³)
Right hippocampal volume (mm ³), mean (SD)	-	4.05 ×10 ³ (0.49×10 ³)	4.04 ×10 ³ (0.49×10 ³)
Total brain volume (mm ³), mean (SD)	-	1116.40×10 ³ (120.73×10 ³)	1115.78×10 ³ (120.02×10 ³)
eTIV(mm ³), mean (SD)	-	1.56×10 ⁶ (0.16×10 ⁶)	$1.56 \times 10^{6} (0.16 \times 10^{6})$
Mean cortical thickness (mm), mean (SD)	-	2.45 (0.09)	2.45 (0.09)

*Participants with data additionally missing for crystallized intelligence: n=190

[†]Values have not been adjusted for head size. Participants with data additionally missing for individual imaging markers: cortical thickness:

n=17; total brain volume: n=18; hippocampal volume: n=4

[‡]Subset of participants with complete cognitive examination and microRNA expression data

[¶]Cognitive examination z-scores were generated based on summary statistics from the first 5000 participants of the Rhineland Study.



Figure 1: Replication of previous findings on microRNAs associated with cognition, AD or MCI.

Replication of microRNAs that were identified as associated with cognition in previous cross-sectional population-based studies [12–16] (A), one previous longitudinal population-based study (B) [13], and a previous meta-analysis of microRNAs dysregulated in AD and MCI (C) [17]. Details on the studies included can be found in **Supplementary Table S1.** The sample sizes of included studies are in parentheses next to study names. Statistical significance is indicated by the asterisks. MicroRNAs that appeared in multiple included studies are marked with "†". MicroRNAs are marked with "+" in parentheses when their higher expression was associated with better cognitive function in included studies, and with "-" in the opposite case. For the AD and MCI meta-analysis, "+" indicates higher expression of the microRNA in controls compared to patients. MicroRNAs that were significantly associated with blue color and are outlined with a blue box. Annotated with red color are microRNAs that were significantly associated with cognition in our study, but in an opposite direction compared to included studies. Abbreviations: AD, Alzheimer's Disease; MCI, Mild Cognitive Impairment; SD, Standard Deviation



Figure 2: Hypothesis-free association of microRNA and module expression with cognition.

(A, B) Linear regression coefficients and significance levels for the association between co-expression modules and cognitive scores. Shown are Model 1 (A) which was adjusted for age and sex, and Model 2 (B) which was additionally adjusted for first (native) language and educational level. Modules are named after colors, and numbers in parentheses indicate the number of microRNAs within each module. Significance was determined after correcting for multiple comparisons with the fdr method. (C) Volcano plots of the *per microRNA* association of all microRNAs measured in our study with global cognition, executive function and episodic verbal memory scores. The *P* value shown in the y-axis has not been corrected for multiple testing. Top microRNAs for each score are annotated and co-expression modules are shown in parentheses. MicroRNAs that reached statistical significance for at least one phenotype, after multiple testing correction (fdr ≤ 0.05), are shown with triangles and have been marked with an asterisk (*). Hub microRNAs are annotated with blue color. Abbreviations: fdr, false discovery rate; SD, Standard Deviation



Figure 3: Association of microRNA expression with cognitive scores and brain imaging measures. The heatmap (**A**) shows the association of microRNA expression with cognitive scores and brain imaging measures. Included were microRNAs identified as associated with cognition in our literature replication, *co-expression* and *per microRNA* analyses. The association of some microRNAs with cognitive domain scores was modified by sex and age. This is illustrated in (**B**) for sex and (**C**) for age, which show the standardized regression betas and 95% confidence intervals for the sex- and age-stratified association of these microRNAs with each cognitive score. Linear regression analyses were based on Model 1, which included as covariates age and sex, except for the sex-stratified analysis which was controlled only for age. Abbreviations: SD, Standard Deviation; fdr, false discovery rate; HCV, Hippocampal Volume; CI, Confidence Interval

Association of microRNA expression with regional cortical thickness



Figure 4: Region-specific association between microRNA expression and brain cortical thickness. Regions of interest have been mapped based on the Desikan-Killiany cortical atlas. The color indicates the standardized β for the regions in which microRNA expression was significantly associated with cortical thickness. The analysis was performed only for microRNAs that were significantly associated with cognition and mean cortical thickness across both hemispheres. The visualization was created with the *ggseg* (v. 1.6.5) and *ggsegDKT* (v. 1.0.1.1) R packages [75]. Abbreviations: SD, Standard Deviation





Figure 5: Tissue expression analysis of cognition-related microRNAs

Boxplots of tissue expression of microRNAs associated with cognition. Data was obtained from the microRNA Tissue Atlas [32], based on post-mortem samples taken from 6 human donors (here indicated by the colored dots). The module each microRNA belongs to is shown in parentheses. The top 5 tissues for each microRNA, based on median microRNA expression, are shown. Note that, to allow for better comparison of relative expression in tissues for each microRNA, the scale of the x-axis (expression z-score) varies.

Most enriched pathways for microRNA target genes per co-expression module



MicroRNA

Figure 6: Function genomics analysis of cognition-related microRNAs

(A) Results of Gene Ontology: Biological Processes enrichment analysis of negatively associated target genes of the microRNAs in each co-expression module. The top 10 most enriched terms (based on P values) are shown. The numbers in parentheses indicate the number of target genes in each enriched term. P values have been corrected for multiple testing using the fdr method. Note that, to allow for better comparison of relative enrichment in each module, the scale of the x-axis (negative logarithm of fdr) varies. (B) Overlap and overrepresentation (determined with a hypergeometric test) of negatively associated target genes of microRNA in a GWAS of global cognitive function [36].